English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Purpose   To compare the differential diagnostic values of  18 F-Alfatide II PET/CT between tuberculosis and lung cancer patients and in patients with sarcoidosis and common inflammation.Methods   Nine inflammation patients (4 tuberculosis, 3 sarcoidosis, and 2 common inflammation) and 11 lung cancer patients were included in this study. All patients underwent  18 F-FDG and  18 F-Alfatide II PET/CT within 2 weeks, followed by biopsy and surgery. The maximized standard uptake value (SUVmax) and the mean standard uptake value (SUVmean) were evaluated.Results   The active tuberculosis lesions showed a high accumulation of  18 F-FDG, but varying degrees of accumulation of  18 F-Alfatide II, including negative results. The SUVmax of  18 F-Alfatide II in malignant lesions was significantly higher than that in tuberculosis (4.08 ± 1.51 versus 2.63 ± 1.34,  P  = 0.0078). Three patients with sarcoidosis showed negative results in  18 F-Alfatide II PET/CT.Conclusions   The expression of  α  V  β  3  is much lower in tuberculosis as compared to that in lung cancer, and accumulation of  18 F-Alfatide II varied even in lesions of the same patient. The negative results of sarcoidosis patients led to the speculation that  α  V  β  3  was not expressed in those lesions.

Comparing the Differential Diagnostic Values of 18F-Alfatide II PET/CT between Tuberculosis and Lung Cancer Patients

Comparing the Differential Diagnostic Values of ¹⁸F-Alfatide II PET/CT between Tuberculosis and Lung Cancer Patients